Chronic kidney disease as a global public health problem: Approaches and initiatives - A position statement from Kidney Disease Improving Global Outcomes

Kidney International

Volumn 72, Issue 3, 2007, Pages 247-259

  Levey, A S ^a   Atkins, R ^b   Coresh, J ^c   Cohen, E P ^d   Collins, A J ^e   Eckardt, K U ^f   Nahas, M E ^g   Jaber, B L ^h   Jadoul, M ⁱ   Levin, A ^j   Powe, N R ^k   Rossert, J ^l   Wheeler, D C ^m   Lameire, N ⁿ   Eknoyan, G ^o  

^a TUFTS MEDICAL CENTER   (United States)

^b MONASH UNIVERSITY   (Australia)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g Sheffield Kidney Institute   (United Kingdom)

^h ST ELIZABETH'S MEDICAL CENTER   (United States)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k DEPARTMENT OF PATHOLOGY   (United States)

^l HÔPITAL TENON   (France)

^m ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁿ GHENT UNIVERSITY HOSPITAL   (Belgium)

^o BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Cancer; Cardiovascular disease; Chronic infection; Chronic kidney disease; Public health; Screening

Indexed keywords

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMMUNITY; COMPREHENSION; CONFERENCE PAPER; DISEASE COURSE; HEALTH CARE ORGANIZATION; HUMAN; INFECTION; KIDNEY FUNCTION; LABORATORY TEST; OUTCOME ASSESSMENT; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; RISK FACTOR; RISK REDUCTION; SCREENING;

EID: 34547461117     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002343     Document Type: Conference Paper

References (89)

1. Levey AS, Andreoli SP, DuBose T et al. Chronic kidney disease: common, harmful and treatable - World Kidney Day 2007. Am J Kidney Dis 2007; 49: 175-179.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39(Suppl 1): S1-S266.
3. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
4. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100.
5. Coresh J, Byrd-Holt D, Astor BC et al. Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol 2005; 16: 180-188.
6. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
7. de Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular risk marker and a new target for therapy. Kidney Int Suppl 2005; 98: S25-S29.
8. Chen J, Wildman RP, Gu D et al. Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years. Kidney Int 2005; 68: 2839-2845.
9. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284.
10. Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 2003; 14(Suppl 2): S131-S138.
11. Keith D, Nicholls G, Guillion C et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41(Suppl 3): S1-S92.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S1-S202.
14. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(Suppl 1): S1-S290.
15. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3): S1-S145.
16. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
17. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
18. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 2006; 29(Suppl 1): S1-S85.
19. World Health Organization. Preventing chronic diseases: a vital investment: WHO global report. 2005. Geneva; Ref Type: Report.
20. Yach D, Hawkes C, Gould CL et al. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004; 291: 2616-2622.
21. Fried LF, Katz R, Sarnak MJ et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005; 16: 3728-3735.
22. Eknoyan G, Lameire N, Barsoum R et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004; 66: 1310-1314.
23. Mann JFE, Gerstein HC, Qi-Long Y et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641-647.
24. Boulware LE, Jaar BG, Tarver-Carr ME et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290: 3101-3114.
25. Atthobari J, Asselbergs FW, Boersma C et al. Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE inhibitor to prevent cardiovascular events: a pharmacoeconomic analysis linked to the PREVEND and the PREVEND IT studies. Clin Ther 2006; 28: 432-444.
26. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13(Suppl 1): S37-S40.
27. US Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2005 Ref Type: Report.
28. National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45(Suppl 3): S1-S154.
29. McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens 2004; 13: 591-600.
30. Barsoum RS. Malarial acute renal failure. J Am Soc Nephrol 2000; 11: 2147-2154.
31. Barsoum R. The changing face of schistosomal glomerulopathy. Kidney Int 2004; 66: 2472-2484.
32. Altintepe L, Tonbul HZ, Ozbey I et al. Urinary tuberculosis: ten years' experience. Ren Fail 2005; 27: 657-661.
33. Shaheen FA, Al-Khader AA. Preventive strategies of renal failure in the Arab world. Kidney Int Suppl 2005; 98: S37-S40.
34. Lai AS, Lai KN. Viral nephropathy. Nat Clin Pract Nephrol 2006; 2: 254-262.
35. Shah SN, He CJ, Klotman P. Update on HIV-associated nephropathy. Curr Opin Nephrol Hypertens 2006; 15: 450-455.
36. Foley RN. Infections and cardiovascular disease in patients with chronic kidney disease. Adv Chronic Kidney Dis 2006; 13: 205-208.
37. Jaber BL. Bacterial infections in hemodialysis patients: pathogenesis and prevention. Kidney Int 2005; 67: 2508-2519.
38. Foley RN, Guo H, Snyder JJ et al. Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol 2004; 15: 1038-1045.
39. Allon M, Depner TA, Radeva M et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003; 14: 1863-1870.
40. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58: 1758-1764.
41. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001; 120: 1883-1887.
42. Health Topics. World Health Organization. 10-19-2006. Ref Type: Electronic Citation.
43. Lewden C, Raffi F, Cuzin L et al. Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiproteases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study. J Infect Dis 2002; 186: 710-714.
44. Gardner LI, Holmberg SD, Williamson JM et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 203-209.
45. Gardner LI, Klein RS, Szczech LA et al. Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr 2003; 34: 320-330.
46. Szczech LA, Gupta SK, Habash R et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66: 1145-1152.
47. Szczech LA, Hoover DR, Feldman JG et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39: 1199-1206.
48. Levin A, Joy R, Djurdjev O et al. Baseline glomerular filtration rate o60 ml/min is associated with increased mortality among HIV patients on antiviral therapy [abstract]. J Am Soc Nephrol. 2006; 17: 803A.
49. Fontana RJ, Hann HW, Perrillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727.
50. Tsui JI, Vittinghoff E, Shlipak MG et al. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006; 17: 1168-1174.
51. Huang JF, Chuang WL, Dai CY et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med 2006; 260: 255-262.
52. Huang E, Hewitt RG, Shelton M et al. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 1996; 16: 222-229.
53. Noormohamed SE, Katseres JK, Stapleton JT. Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals. Ren Fail 1998; 20: 627-633.
54. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
55. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
56. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
57. Gupta SK, Eustace JA, Winston JA et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585.
58. Cho ME, Kopp JB. HIV and the kidney: a status report after 20 years. Curr HIV/AIDS Rep 2004; 1: 109-115.
59. Lucas GM, Eustace JA, Sozio S et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18: 541-546.
60. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
61. Mehta N, Reilly M. Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population. HIV Clin Trials 2005; 6: 5-24.
62. Morales JM, Morales E, Andres A, Praga M. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens 1999; 8: 205-211.
63. Meyers CM, Seeff LB, Stehman-Breen CO et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-657.
64. American Society of Transplant Surgeons and American Society of Transplantation. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004; 4: 160-163.
65. Dinits-Pensy M, Forrest GN, Cross AS et al. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005; 46: 997-1011.
66. Kausz AT, Gilbertson DT. Overview of vaccination in chronic kidney disease. Adv Chronic Kidney Dis 2006; 13: 209-214.
67. Fraser GM, Ochana N, Fenyves D et al. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. J Hepatol 1994; 21: 450-454.
68. DaRoza G, Loewen A, Djurdjev O et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42: 1184-1192.
69. Dash A, Galsky MD, Vickers AJ et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107: 506-513.
70. Murray PT, Ratain MJ. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol 2003; 21: 2633-2635.
71. Séronie-Vivien S, Toullec S, Malard L et al. Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients. Med Oncol 2006; 23: 63-73.
72. Holweger K, Bokemeyer C, Lipp HP. Accurate assessment of individual glomerular filtration rate in cancer patients: an ongoing challenge. J Cancer Res Clin Oncol 2005; 131: 559-567.
73. Lefaucheur C, Stengel B, Nochy D et al. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high risk cancer association. Kidney Int 2006; 70: 1510-1517.
74. Launay-Vacher V, Oudard S, Janus N et al. Renal insufficiency in cancer patients: prevalence and implications on anticancer drugs management. Results of the 'IRMA' study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 2006; 24: 8603.
75. Huang WC, Levey AS, Serio AM et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective study. Lancet Oncology 2006; 7: 735-740.
76. Stewart JH, Buccianti G, Agodoa L et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003; 14: 197-207.
77. Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine 1990; 69: 217-226.
78. Farivar-Mohseni H, Perlmutter AE, Wilson S et al. Renal cell carcinoma and end-stage renal disease. J Urol 2006; 175: 2018-2021.
79. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 196: 2823-2831.
80. Xue JL, Dalleska F, Murray AM et al. Cancer prevalence in patients with ESRD [abstract]. J Am Soc Nephrol 2005; 16: 726a.
81. Chertow GM, Paltiel AD, Owen WF et al. Cost effectiveness of cancer screening in end-stage renal disease. Arch Intern Med 1996; 156: 1345-1350.
82. Irie F, Iso H, Sairenchi T et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69: 1264-1271.
83. Lever AF, Hole DJ, Gillis CR et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-184.
84. Pedersen LM, Milman N. Microalbuminuria in patients with lung cancer. Eur J Cancer 1998; 34: 76-80.
85. Cassidy J, Twelves C, Van Cutsem E et al. First line oral capecitabine therapy in metastatic colorectal cancer: safety profile compared to intravenous 5-FU/leucovorin. Ann Oncol 2002; 13: 566-575.
86. Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine based methodologies. Eur J Cancer 2002; 38: 11-16.
87. Menon V, Sarnak MJ, Levey AS. Risk factors and kidney disease. In: Brenner BM (ed) The Kidney. (in press) 2007.
88. Kotzmann H, Schmidt A, Scheuba C et al. Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma. Thyroid 1999; 9: 943-947.
89. Pedersen LM, Johnsen HE. Microalbuminuria is associated with impaired glomerular permselectivity in lymphoma patients. Scand J Clin Lab Invest 2005; 65: 477-484.